PTC Therapeutics, Inc. Lease, Cost
PTC Therapeutics, Inc. (PTCT) reported Lease, Cost of $2.56 million for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2020-08-05
- PTC Therapeutics, Inc. lease, cost for the quarter ending 2020-06-30 was $2.56M, a 136.62% increase year-over-year.
- PTC Therapeutics, Inc. lease, cost for the quarter ending 2020-03-31 was $2.42M, a 140.38% increase year-over-year.
- PTC Therapeutics, Inc. lease, cost for the quarter ending 2019-12-31 was $2.17M.
- PTC Therapeutics, Inc. lease, cost for the quarter ending 2019-09-30 was $1.71M.
- PTC Therapeutics, Inc. lease, cost for fiscal 2019 was $5.97M.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2020-06-30 | $2.56M 10-Q · filed 2020-08-05 | $4.99M 10-Q · filed 2020-08-05 | $7.16M derived: sum of 3 quarters · filed 2020-08-05 | $8.87M derived: sum of 4 quarters · filed 2020-08-05 |
| 2020-03-31 | $2.42M 10-Q · filed 2020-04-30 | $4.59M derived: sum of 2 quarters · filed 2020-04-30 | $6.30M derived: sum of 3 quarters · filed 2020-04-30 | $7.39M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $3.88M derived: sum of 2 quarters · filed 2020-03-02 | $4.96M derived: sum of 3 quarters · filed 2020-08-05 | $5.97M 10-K · filed 2020-03-02 |
| 2019-09-30 | $1.71M 10-Q · filed 2019-10-30 | $2.79M derived: sum of 2 quarters · filed 2020-08-05 | $3.80M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $1.08M 10-Q · filed 2020-08-05 | $2.09M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $1.01M 10-Q · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |